Iovance
Iovance’s Amtagvi gains FDA accelerated approval for melanoma treatment
February 19, 2024Medical Communications Iovance, Oncology, accelerated approval, melanoma
Iovance Biotherapeutics has announced that the US Food and Drug Administration (FDA) has approved Amtagvi (lifileucel) suspension for intravenous infusion …
